1.
Characterization of specific biomarkers and functional properties of human cancer progenitor cells isolated from diverse malignant tissues and cancer cell lines
| Malignant Tissue/ Established cancer cell line | Specific biomarkers/Stem cell-like properties |
|---|---|
| Hematological malignancy | |
| Acute myeloid leukemia (AML) | CD34+/CD38−, Thy 1−, KIT−, Leukaemic grafts in vivo |
| Multiple myeloma and RPMI 8226 and NCI-H929 myeloma cells | CD138−, Leukaemic grafts in vivo |
| Pediatric brain tumor | |
| Primary medulloblastoma, astrocytoma, glioblastoma multiforme and ependymoma | CD133+/nestin+, Neurospheres, Tumorigenic in vivo |
| Primary gangliogliom | CD133+/nestin+, Neurospheres |
| Adult brain tumor | |
| Primary glioblastoma multiforme | CD133+/nestin+, Neurospheres, Tumorigenic in vivo |
| Melanoma | |
| Metastatic melanoma | CD20+, Melanoma spheroids |
| Primary WM115 melanoma cell line | CD20+, Melanoma spheroids |
| Metastatic WM239A melanoma cell line | CD20+, Melanoma spheroids |
| Breast cancer | |
| Primary and metastatic breast cancers | CD44+/CD24−low, Oct-3/4, Mammospheres, Tumorigenic in vivo |
| MCF-7 breast cancer cell line | CD44+/CD24−low, Mammospheres, Tumorigenic in vivo |
| Ovarian cancer | |
| A2 clone from primary ovarian cancer | CD44+, Oct-3/4, Nanog, EGFR, Vimentin, E-cadherin Tumorigenic in vivo |
| A4-T spontaneously transformed clone | CD44+, Oct-3/4, Nanog, EGFR, Vimentin/Snail, Tumorigenic in vivo, A4-T > A2 clone |
| Prostatic cancer | |
| Primary and metastatic prostatic adenocarcinomas | CD133+/CD44+/α2β1-integrinhigh, Prostatespheres |
| LAPC-4, LAPC-9 and DU 145 prostatic cancer cell lines or xenografts | CD44high/SMO+/β-catenin, Tumorigenic in vivo |
| PC3 prostatic cancer cell line | CD44high/ CD133 |
| Pancreatic cancer | |
| Primary pancreatic adenocarcinoma | CD44+/CD24+/ESA+, Tumorigenic in vivo |
| PancTuI and A81 8–6 pancreatic cancer cell line | CD133+/ABCG2+ |
| Colorectal cancer | |
| Colorectal adenocarcinoma | CD133+, colon spheres, Tumorigenic in vivo |
| Head and neck cancer | |
| Head and neck squamous cell carcinoma | CD44+, Tumorigenic in vivo |
ABCG2/BCRP, breast cancer resistance protein;ESA, epithelial-specific antigen.